What is a stock summary page? Click here for an overview.
Business Description
Editas Medicine Inc
NAICS : 325412
SIC : 2834
ISIN : US28106W1036
Description
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.71 | |||||
| Equity-to-Asset | 0.39 | |||||
| Debt-to-Equity | 0.26 | |||||
| Debt-to-EBITDA | -0.15 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -7.2 | |||||
| Beneish M-Score | -1.4 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 1.2 | |||||
| 3-Year EBITDA Growth Rate | -0.6 | |||||
| 3-Year EPS without NRI Growth Rate | 1.4 | |||||
| 3-Year FCF Growth Rate | -1.6 | |||||
| 3-Year Book Growth Rate | -41.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 25.29 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -44.32 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.93 | |||||
| 9-Day RSI | 36.78 | |||||
| 14-Day RSI | 40.57 | |||||
| 3-1 Month Momentum % | 46.56 | |||||
| 6-1 Month Momentum % | -40.37 | |||||
| 12-1 Month Momentum % | -72.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.75 | |||||
| Quick Ratio | 3.75 | |||||
| Cash Ratio | 3.5 | |||||
| Days Sales Outstanding | 61.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.5 | |||||
| Shareholder Yield % | -0.24 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -739.4 | |||||
| Net Margin % | -733.74 | |||||
| FCF Margin % | -678.09 | |||||
| ROE % | -100 | |||||
| ROA % | -59.47 | |||||
| ROIC % | -170.78 | |||||
| 3-Year ROIIC % | 44.95 | |||||
| ROC (Joel Greenblatt) % | -498.34 | |||||
| ROCE % | -72.85 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.87 | |||||
| PB Ratio | 0.69 | |||||
| Price-to-Tangible-Book | 0.69 | |||||
| EV-to-EBIT | 0.57 | |||||
| EV-to-Forward-EBIT | -2.09 | |||||
| EV-to-EBITDA | 0.59 | |||||
| EV-to-Forward-EBITDA | -2.12 | |||||
| EV-to-Revenue | -4.25 | |||||
| EV-to-Forward-Revenue | 9.13 | |||||
| EV-to-FCF | 0.63 | |||||
| Price-to-GF-Value | 0.14 | |||||
| Price-to-Net-Current-Asset-Value | 1.13 | |||||
| Price-to-Net-Cash | 1.47 | |||||
| Earnings Yield (Greenblatt) % | 175.44 | |||||
| FCF Yield % | -235.77 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EDIT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Editas Medicine Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 32.313 | ||
| EPS (TTM) ($) | -2.88 | ||
| Beta | 1.76 | ||
| 3-Year Sharpe Ratio | -0.58 | ||
| 3-Year Sortino Ratio | -0.81 | ||
| Volatility % | 88.12 | ||
| 14-Day RSI | 40.57 | ||
| 14-Day ATR ($) | 0.155086 | ||
| 20-Day SMA ($) | 1.38225 | ||
| 12-1 Month Momentum % | -72.05 | ||
| 52-Week Range ($) | 1.12 - 7.09 | ||
| Shares Outstanding (Mil) | 82.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Editas Medicine Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Editas Medicine Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Editas Medicine Inc Frequently Asked Questions
What is Editas Medicine Inc(EDIT)'s stock price today?
The current price of EDIT is $1.12. The 52 week high of EDIT is $7.09 and 52 week low is $1.12.
When is next earnings date of Editas Medicine Inc(EDIT)?
The next earnings date of Editas Medicine Inc(EDIT) is 2025-05-08 Est..
Does Editas Medicine Inc(EDIT) pay dividends? If so, how much?
Editas Medicine Inc(EDIT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers